PN 20
Alternative Names: PN-20Latest Information Update: 02 Aug 2024
At a glance
- Originator Chongqing Peg-Bio Biopharm
- Class Antithrombotics; Chemoprotectants
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thrombocytopenia
Most Recent Events
- 05 Jan 2024 Chongqing Peg-Bio Biopharm completes a phase I trial in Thrombocytopenia (Chemotherapy-induced, In volunteers) in China (NCT06523088)
- 06 Dec 2023 Chongqing Peg-Bio Biopharm initiates a Phase-I clinical trials in Thrombocytopenia (Chemotherapy-induced, Prevention) in China (SC) (NCT06521931)
- 16 Jun 2022 Phase I trial in Thrombocytopenia (Chemotherapy-induced, In volunteers) in China (NCT06523088)